Although either singleanti-PD-1 or anti-GITR mAb exhibited little antitumor effect, combined anti-PD-1/GITRmAb treatment significantly prolonged overall survival time of mice (Figure 1B; median survival time 31.50, 34.00, 33.00 or >75.00 days forcontrol, anti-PD-1, anti-GITR or anti-PD-1/GITR mAb group respectively; p < 0.01,combined mAb compared to single or control mAb) with 20% (2 out of 10 mice) of miceremaining tumor-free (confirmed by laparotomy) 90 days after tumor challenge (Figure1C). The gene discussed is TNFRSF18; the disease is neoplasm.